Articles tagged with: Decadron
News»
Results from a Spanish Phase 3 clinical trial suggest that initial treatment with a combination of Velcade, thalidomide, and dexamethasone may lead to better responses before and after stem cell transplantation, as compared to treatment with thalidomide and dexamethasone alone. In addition, treatment with the three-drug combination increases progression-free survival time.
The study investigators concluded that their findings support the use of a combination of Velcade (bortezomib), thalidomide (Thalomid), and dexamethasone (Decadron), often referred to as VTD, as initial treatment in newly diagnosed myeloma patients who are eligible for …
NewsFlash »
Phase 1 Trial Of All-Oral Ricolinostat-Revlimid-Dexamethasone Combo Begins – Acetylon Pharmaceuticals announced last week the initiation of a Phase 1b clinical trial of ricolinostat (ACY-1215) in combination with Revlimid (lenalidomide) and dexamethasone (Decadron) for the treatment of patients with relapsed or refractory multiple myeloma. Ricolinostat is an oral treatment that belongs to a family of anti-cancer drugs called HDAC inhibitors. Other HDAC inhibitors under investigation for multiple myeloma include Zolinza (vorinostat) and panobinostat. Acetylon believes that ricolinostat could produce fewer side effects than other non-specific HDAC inhibitors, as it selectively inhibits the enzyme HDAC6. The primary aim of the trial is to establish an optimal dose of ricolinostat over a 28-day treatment cycle and to assess the potential anti-myeloma activity of the three-drug combination. In addition, Acetylon is enrolling patients for a Phase 1/2 trial of ricolinostat in combination with Velcade (bortezomib) and dexamethasone in patients with relapsed or refractory myeloma. For more information on both trials, please see the Acetylon press release and the U.S. clinical trial registry.
Lucatumumab Shows Modest Activity As Single Agent In Relapsed/Refractory Myeloma – Results from a recent Phase 1 study indicate that lucatumumab, an antibody developed by Novartis, is well tolerated in relapsed or refractory myeloma patients; however, the compound only showed modest activity in the study participants. Specifically, 4 percent of patients maintained a partial response for a period of eight months or longer, and 43 percent maintained stable disease. The most common severe side effects included anemia (7 percent), chills (7 percent), and fever (7 percent). Side effects severe enough to limit drug dosage were seen in about 10 percent of patients. Based on these results, the researchers recommend that lucatumumab be tested in combination with other anti-myeloma drugs. For more information, please see the study in the British Journal of Hematology (abstract).
Viracept-Velcade Combo Kills Myeloma Cells Better Than Either Drug Alone – Researchers at the National Cancer Institute have found that a combination of the anti-HIV drug Viracept (nelfinavir) and Velcade kills myeloma cells better than either drug alone in a preclinical study. Viracept belongs to a class of drugs called protease inhibitors and was approved by the FDA to treat HIV in 1997. Both Viracept and Velcade limit a cell’s ability to chop up and discard unwanted proteins. Simultaneous treatment with both drugs resulted in an accumulation of such unwanted proteins in the cell, eventually resulting in cell death. For more information, please refer to the study in Cell Death and Disease.
News»
Results from a recent retrospective study confirm that treatment with a combination of Revlimid and dexamethasone slows disease progression and improves survival in elderly patients with relapsed or refractory myeloma.
However, findings from the study also indicate that certain side effects, such as anemia and blood clots, occurred more frequently in elderly patients.
Novel agents such as Revlimid (lenalidomide), thalidomide (Thalomid), and Velcade (bortezomib) are commonly used to treat relapsed and refractory myeloma.
A previous study found that Revlimid in combination with dexamethasone (Decadron) is effective in patients …
News»
The results of a recent Phase 3 study conducted throughout Europe show that treatment with a combination of Velcade, thalidomide, and dexamethasone leads to superior clinical benefits compared to treatment with thalidomide and dexamethasone alone in multiple myeloma patients who have relapsed or progressed after a stem cell transplant.
Specifically, more patients responded to the three-drug regimen. In addition, the group of patients treated with the three-drug combination responded longer and did not progress as quickly as those treated with the two-drug combination. However, the three-drug combination led to a higher rate …
Opinion»
For one day each week, my children have a special nickname for me. It’s Tyrannosaurus Dex!
I suppose that it is fitting that a wise-guy has wise-guy children! Here’s how I earned this tongue-in-cheek moniker.
Like many multiple myeloma patients, I have a love / hate relationship with the potent corticosteroid, dexamethasone (Decadron), also called dex for short. I love that dex offers positive health benefits to many of us facing a diagnosis of myeloma. Conversely, I hate that dex is also known to cause a wide array of side effects …
News»
Interim results from three clinical trials suggest that MLN9708, as a single agent or in combination with Revlimid and dexamethasone, may be an effective and well tolerated treatment for both previously untreated multiple myeloma patients and patients with relapsed or refractory disease.
Findings from the three trials were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago earlier this month.
According to Dr. Irene Ghobrial from the Dana Farber Cancer Institute in Boston, who presented a review of some of the MLN9708 results at ASCO, the response rates …
News»
Today concludes this year’s American Society of Clinical Oncology (ASCO) annual meeting, which began on Friday in Chicago. However, yesterday was the last day with any multiple myeloma-related sessions.
During yesterday’s poster session, important new research findings were summarized on posters throughout a large conference hall.
The studies were on a wide variety of myeloma-related topics ranging from new treatments being developed for myeloma, to currently used regimens, to secondary cancers, to precursor myeloma diseases, and much more.
This update covers some of the myeloma-related studies presented during the poster session, in …